EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN

Hong Sun, Yong Huang, Lynda Frassetto, and Leslie Z. Benet

Department of Biopharmaceutical Sciences (H.S., Y.H., L.Z.B.), Division of Clinical Pharmacology and Experimental Therapeutics (H.S.); and Department of Medicine and General Clinical Research Center (L.F.), University of California, San Francisco, California

Received May 7, 2004; accepted July 30, 2004

ABSTRACT:

Hepatic clearance of erythromycin (Ery) is significantly reduced in patients with end stage renal disease. Since Ery is primarily eliminated via excretion of unchanged drug in the bile, we suspect that this change could be due to the effect of uremic toxins on hepatic uptake and/or efflux transporters. Using rat hepatocytes and microsomes as model proof of concept systems, we examined six uremic toxins, 3-carboxy-4-methyl-5-propyl-2-furan-propanoic acid (CMPF), indoxyl sulfate (IS), hippuric acid (HA), indole acetic acid (IA), guanidinosuccinic acid (GSA), and indoxyl-β-glucuronide (IG), for their effects on Ery uptake and metabolism. Ery and the metabolite N-demethyl-Ery were measured by liquid chromatography/tandem mass spectrometry. The uptake of Ery by rat hepatocytes was markedly inhibited by rifampin and digoxin, but not by quinidine, suggesting that Oatp2 plays a major role in the uptake of Ery. At 50 μM, CMPF significantly (p < 0.05) reduced hepatocyte accumulation of Ery and N-demethyl-Ery. At higher concentrations (≥200 μM), CMPF appears to also inhibit the enzymatic metabolism of Ery. In contrast, IS did not significantly inhibit the hepatocyte uptake of Ery, even at the highest concentration (800 μM) tested, but reduced metabolite generation (p < 0.001). The other uremic toxins, HA, IA, IG, and GSA, did not affect either hepatic uptake or microsomal metabolism of Ery. CMPF, IS, and HA were shown not to inhibit differential P-glycoprotein transport of Ery in cellular systems. Our results suggest that CMPF can directly inhibit the uptake of Ery by inhibiting Oatp2, whereas IS is more likely to inhibit the enzymatic metabolism of Ery.

More and more evidence suggests that renal failure affects not only the renal disposition of drugs that are cleared by the kidney, but also the nonrenal disposition of drugs that are metabolized by the liver (Touchee and Slaughter, 1991; Yuan and Venitz, 2000; Dreisbach and Lertora, 2003). Erythromycin (Ery) exhibits significantly reduced nonrenal clearance in patients with end stage renal disease (ESRD) (Welling and Craig, 1978; Kanfer et al., 1987). There have been a number of reports of ototoxicity caused by Ery in ESRD patients, and blood levels of Ery were found to be extremely high in such cases (Kroboth et al., 1983). Furthermore, the exposure to Ery was reported to be about 4- to 5-fold higher in ESRD patients than in healthy controls after a single oral dosing (Kanfer et al., 1987). The markedly increased exposure to Ery in the ESRD patients was most likely due to reduced hepatic clearance, since Ery is mainly eliminated by the hepatobiliary system, with only a small fraction eliminated unchanged in urine. But the underlying mechanisms of this reduced hepatic clearance are not well understood.

In the liver, Ery is partially metabolized by CYP3A4 to N-demethyl-Ery but is primarily excreted unchanged in the bile as stated by Touchee and Slaughter (1991), although a primary reference was not given. Thus, both uptake and efflux transporters may play an important role in the disposition of Ery. Although studies have demonstrated that CYP3A activity was reduced in CRF (chronic renal failure) rats (Leblond et al., 2000; Guevin et al., 2002), we suspect that metabolism changes cannot be the major determinant for a drug in which metabolism is not the primary route of elimination. We hypothesize and tested here whether other mechanisms, such as alteration of transporter activities, might contribute to the reduced hepatic clearance of Ery in renal failure.

Hepatic uptake is the first step and can be rate-limiting in the hepatic elimination of xenobiotics (Yamazaki et al., 1996). Transporters located at the basolateral (sinusoidal) membrane of hepatocytes have been found to be involved in the uptake of many drugs (Faber et al., 2003; Hagenbuch and Meier, 2003). Organic anion transport polypeptides (OATP/Oatp; human/rat) are a class of major drug carrier proteins supporting the sodium-independent hepatic uptake of a large number of organic anions, bulky organic cations, and neutral compounds (Eckhardt et al., 1999; Konig et al., 2000). Substrate
specificity of transporters is broad, and considerable overlap has been observed, although unique features of individual transporters have been demonstrated. Many compounds are both substrates and inhibitors of a transporter. Ery is a bulky organic cation with molecular weight of 734. It is an inhibitor of OATP (Cvetkovic et al., 1999). Most likely, its hepatic uptake is also mediated by OATP/Oatps in the liver. Uremic toxins that accumulate in patients with ESRD cause a number of problems. Organic anions such as 3-carboxy-4-methyl-5-propyl-2-furan-propanoic acid (CMPF), indoxyl sulfate (IS), and hippuric acid (HA), which are derived from dietary protein and normally excreted into urine, accumulate in the body due to the kidney malfunction. They are significantly elevated in the serum of uremic patients with concentrations approaching 800 µM (IS), 400 µM (CMPF), and 2 mM (HA) (Niwa and Ise, 1994). These substances are well known for their inhibitory effects on serum binding of drugs to albumin (Takamura et al., 1997; Sarnatskaya et al., 2002). They were also found to inhibit the active tubular secretion of organic acids by inhibiting renal organic anion transporters (Tsutsumi et al., 2002). As a consequence, the accumulation of these organic acids further stimulates the progression of chronic renal failure (Sato et al., 2003). These uremic toxins might also be involved in altering thyroid function in uremic patients. CMPF and indoxyl sulfate, at concentrations normally present in the serum of uremic patients, were found to inhibit the uptake of thyroxin by rat hepatocytes (Lim et al., 1993).

Based on the above evidence, we hypothesize that circulating uremic toxins can inhibit liver uptake transporters, thereby causing reduced hepatic clearance of drugs in renal failure patients. Note that changes in protein binding cannot explain the reduction in clearance, since increasing free concentrations would lead to increased clearance. Here, we characterized the effects of uremic toxins on the hepatic uptake and metabolism of the probe drug, Ery, using rat hepatocytes and rat microsomes as a proof of concept system.

Materials and Methods

Materials. Erythromycin, rifampin, digoxin, quinidine, indoxyl sulfate, hippuric acid, indole acetic acid, guanidinosuccinic acid and indoxyl-β-glucuronide, oleandromycin, collagenase, and NADPH were purchased from Sigma-Aldrich (St. Louis, MO). CMPF was a generous gift from Professors Masaki Otagiri (Kumamoto University, Kumamoto, Japan) and Edward Lindup (University of Liverpool, Liverpool, UK). Demethyly-erythromycin was purchased from U.S. Pharmacopeia (Evansville, IN). [14C]Erythromycin (48.4 mCi/mmol) was obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). Liver perfusion buffer and hepatocyte washing buffer were purchased from Invitrogen (Carlsbad, CA). Male Wistar rats (250–300 g; Bantin and Kingman, San Leandro, CA) were housed in the UCSF animal care facility with a 12-h light/dark cycle and allowed free access to water and food. Approval of the studies reported here was obtained from the Committee on Animal Research, UCSF. The MDR1-MDCK cell line was generously provided by Dr. Ira Pastan of the National Cancer Institute (Bethesda, MD). GG918 (GF120918) was a gift from GlaxoSmithKline (Uxbridge, Middlesex, UK). All cell culture media were obtained from the UCSF Cell Culture Facility. Transwell inserts and six-well plates were obtained from Costar (Cambridge, MA).

Hepatocyte Isolation. Hepatocytes were isolated as described previously by our laboratory (Lam and Benet, 2004). In brief, male Wistar rats were anesthetized with ketamine/xylazine (12 mg/ml) before surgery. The portal vein was cannulated and perfused with oxygenated liver perfusion buffer for 5 min followed by perfusion with oxygenated hepatocyte washing buffer supplemented with 2 mM L-glutamine, 10 mM Hepes, and 1.2 U/ml collagenase for 5 min at a flow rate of 20 ml/min. The digested liver was excised and hepatocytes were isolated. The hepatocytes were washed three times with ice-cold hepatocyte washing buffer and centrifuged at 50g for 2 min. Cell viability was determined by trypan blue exclusion. Cells exhibiting a greater than 90% viability were used for the experiments.

Hepatocyte Uptake Studies. Before starting the uptake studies, 2 million (in 1 ml of solution) hepatocytes were prewarmed for 5 min in Krebs-Henseleit buffer (pH 7.4) containing 0.21 g/l sodium bicarbonate and supplemented with 10 mM glucose. The uptake studies with erythromycin were initiated by adding [14C]Ery (0.1 µCi, 2 µM) with various inhibitors to the cell suspension. At 5 min, the reaction was terminated by transferring 1 million hepatocytes into a centrifuge tube containing 150 µl of 2 N NaOH under a layer of a 500-µl mixture of silicone oil and mineral oil (density 1.015) (Shitara et al., 2003). After immediately centrifuging at 16,000g for 10 s, the samples were left at 65°C overnight to ensure complete cell lysis. After removal of the oil layer, 150 µl of 2 N HCl and scintillation cocktail were added, and radioactivity was measured using a scintillation counter (LS6000TA; Beckman Coulter, Fullerton, CA). For the uptake studies with unlabeled erythromycin, the separation method was modified to allow the samples to be measured by LC/MS/MS. After the reaction, cells were transferred to a centrifuge tube containing only 500 µl of mixed oil without 2 N NaOH and spun down. After removal of the oil layer, cell pellets were dissolved in 100 µl of H2O and precipitated by 200 µl of acetonitrile containing the internal standard, oleandromycin. The supernatant was then transferred to a vial for LC/MS/MS measurement.

For the kinetic study of Ery uptake, [14C]Ery (2 µM) with various concentrations of unlabeled Ery were incubated with rat hepatocytes at 37°C for 5 min. Based on preliminary studies, a 5-min incubation is within the linear range of Ery uptake by rat hepatocytes. For the inhibition studies, the uptake of unlabeled Ery (2 µM) by rat hepatocytes was measured in the presence or absence of various uremic toxins. The inhibitory effects of CMPF and indoxyl sulfate were further characterized by varying the concentration of these two uremic toxins. Unlabeled Ery was used to allow for measurement of both the parent and metabolite of Ery. Comparing the intracellular ratio of N-demethyl- Ery to Ery allowed us to evaluate which process is affected: uptake, metabolism, and/or efflux, as we demonstrated recently (Lau et al., 2004) for liver perfusion studies.

The effects of uremic toxins on the viability of hepatocytes were also examined. Hepatocytes were incubated with uremic toxins at concentrations used for the inhibition study at 37°C for 5 min; then, the cell viability was assessed by the trypan blue exclusion method. Uremic toxins showed no significant effect on cell viability. Under all uremic toxin-treated conditions, cells exhibited >85% viability.

Microsomal Incubations. Rat liver microsomes were isolated and incubated as described previously by our laboratory (Salphati and Benet, 1999). In brief, isolated rat microsomes (0.75 mg/ml) were incubated with erythromycin in the presence or absence of various concentrations of the uremic toxins in phosphate buffer, NADPH (1 mM) was added to start the reaction. After incubation at 37°C for 10 min, the reaction was stopped by protein precipitation, by addition of an equal volume of acetonitrile containing the internal standard, oleandromycin. The supernatants were stored at −80°C for LC/MS/MS measurement.

FIG. 1. Eadie-Hofstee plot of the uptake of [14C]Ery in rat hepatocytes. [14C]Ery (2 µM) with various amounts of unlabeled Ery were incubated with rat hepatocytes at 37°C for 5 min. Each symbol represents the mean ± S.E.M. (n = 3). The solid line represents the best fit, and the r2 value for the regression is 0.99.
Transport Experiments. The transport experiments were adapted with modifications from Zhang and Benet (1998). Briefly, the cells were washed once and preincubated for 20 min at 37°C in 5% CO₂ in Hanks’ balanced salt solution with 22.5 mM HEPES (HBSS-H). For measuring drug secretion (B→A), 2.5 ml of HBSS-H solution containing the drug was put into the basolateral (B) side and 1.5 ml of HBSS-H was put into the apical (A) side. At selected times, 200-μl samples were taken from the A side and replaced with fresh HBSS-H. For measuring drug absorption (A→B), the drug solution was put into the A side and samples were taken from the B side. For inhibition studies, the inhibitor was put in both the A and B sides. During the studies, the cells were incubated in a shaking incubator (Boekel Scientific, Feasterville, PA).

LC/MS/MS Measurement of Erythromycin. A Micromass Quattro Ultima instrument (Waters, Milford, MA) with electrospray-positive ionization was used. The multiple reaction monitor was set at 734.3 to 576.3 m/z for Ery, 720.3 to 562.2 m/z for N-demethyl-Ery, and 688.5 to 544.3 m/z for the internal standard, oleandomycin. The cone voltage and collision energy were set at 40 V and 20 eV, respectively. The analytical column was a Keystone BDS C18 (4.6 × 50 mm, 5-μm particle size) column (Thermo Hypersil, Keystone Scientific Operations, Bellefonte, PA). The mobile phase consisted of 30% acetonitrile containing 0.1% formic acid. Five-microliter aliquots were injected, and the flow rate was set at 0.8 ml/min with ¼ split into the mass system. Prior analyses demonstrated that linearity (n = 2 at each level) was observed from 0.078 to 10 μM with a r² of 0.9977. The detection limit was estimated to be 2 nM. Inter- and intraday coefficients of variation were estimated as 7.6% and 5%, respectively.

Data Analysis. The kinetic parameters for the uptake of [14C]Ery were calculated using the following equation: 

\[ V_0 = \frac{V_{\text{max}} \times S}{K_m + S} + P_{\text{diff}} \times S \]

where \( V_0 \) is the initial uptake rate (pmol/min/million cells), \( S \) is the substrate concentration (μM), \( K_m \) is the Michaelis-Menten constant (μM), \( V_{\text{max}} \) is the maximum uptake rate, and \( P_{\text{diff}} \) is the nonsaturable diffusion process (μl/min/million cells). To obtain the kinetic parameters, the data were

![Fig. 2](https://via.placeholder.com/150)

**Fig. 2.** Effects of various Oatp inhibitors on the total (A) and active (B) uptake of [14C]Ery by rat hepatocytes. [14C]Ery (2 μM) was incubated with 100 μM rifampin (Rif), quinidine (Qin), and digoxin (Dig). The total uptake of Ery in the absence of inhibitors was 29.4 ± 5.9 pmol/min/million cells, of which active uptake was estimated to be 35%. Uptake of Ery in the presence of inhibitors was expressed as the percentage of the respective controls (in the absence of inhibitors). Each column and bar represents the mean ± S.E.M. (n = 3). *, p < 0.05.
fitted to the above equation using a nonlinear least-squares method by Sigma Plot 2001 (Version 7.1; SPSS Inc., Chicago, IL). The input data were weighted as the reciprocal of the observed values. Student’s $t$ test was used to analyze differences between two groups. Analysis of variance was used to analyze differences among more than two groups, and the significance of difference between two means in these groups was evaluated using Bonferroni’s multiple comparison test. The $p$ value for statistical significance was set at $< 0.05$.

**Results**

**Uptake of Erythromycin by Rat Hepatocytes.** $[^{14}C]$Ery (2 $\mu$M) with various concentrations of unlabeled Ery were incubated with 2 million rat hepatocytes for 5 min to determine the kinetic parameters. The Eadie-Hofstee plot of the data is shown in Fig. 1. Both a saturable component and a nonsaturable component were observed. The fitted kinetic parameters were $72.0 \pm 20.4$ $\mu$M for $K_m$, 276.0 $\pm 51.8$ pmol/min/million cells for $V_{max}$, and 3.3 $\pm 0.1$ $\mu$l/min/million cells for $P_{diff}$. The saturable component estimated by $V_{max}/K_m$ accounts for about 55% of the total uptake.

To determine whether uptake of Ery was mediated by Oatp, Ery was incubated with rat hepatocytes in the presence of various Oatp inhibitors. Quinidine and digoxin are relatively specific inhibitors of Oatp1 and Oatp2, respectively, whereas rifampin is an inhibitor of both Oatp1 and Oatp2 (Shitara et al., 2002). At concentrations of 100 $\mu$M, both rifampin and digoxin significantly inhibited the uptake of Ery (Fig. 2), whereas quinidine did not have any effect. This is even more obvious when only the active transport of Ery is compared, as depicted in Fig. 2B. The inhibition profiles suggest that Ery uptake is mediated by Oatp2 in rat hepatocytes.

**Inhibitory Effects of Uremic Toxins on Hepatocyte Uptake of Erythromycin.** To determine the inhibitory effects of uremic toxins on the uptake of Ery, rat hepatocytes were incubated with unlabeled Ery (2 $\mu$M) in the presence of 400 $\mu$M CMPF, 800 $\mu$M IS, 2 mM HA, 80 $\mu$M indole acetic acid (IA), 320 $\mu$M guanidinosuccinic acid (GSA), and 500 $\mu$M indoxyl-$\beta$-D-glucuronide (IG) at 37°C for 5 min. The chosen concentration of each uremic toxin represents the highest measured value reported in uremic patients (Vanholder et al., 2003). Among the six toxins tested, CMPF was the only one exhibiting significant inhibition on the uptake of Ery (Fig. 3A) as determined by measuring intracellular Ery concentrations. In the CMPF-treated

![Graph A](image1)

**FIG. 3.** Inhibition of Ery uptake of by uremic toxins. The uptake of Ery (2 $\mu$M) by rat hepatocytes was measured in the presence of CMPF (400 $\mu$M), IS (800 $\mu$M), HA (2 mM), GSA (320 $\mu$M), IA (80 $\mu$M), and IG (500 $\mu$M). The amount of intracellular Ery (A) and N-demethyl-Ery (B) in the presence of uremic toxins was expressed as the percentage of control (in the absence of uremic toxins). Each column and bar represents the mean $\pm$ S.E.M. ($n = 3$). *** $p < 0.001$. 

![Graph B](image2)
hepatocytes, the intracellular concentration of Ery was 45.5 ± 4.1% (p < 0.001) of the control. Since 55% of Ery hepatic uptake is estimated to be mediated by transporters (Fig. 1) as discussed above, CMPF at the concentration (400 μM) tested completely blocked the Oatp2-mediated uptake. The intracellular metabolite of Ery showed a comparable reduction (34.1 ± 5.3%, p < 0.001) (Fig. 3B). IS, IA, HA, IG, and GSA had no effect on the hepatic uptake of Ery (Fig. 3A). On the other hand, although IS did not inhibit the uptake of Ery, it significantly reduced the intracellular concentration of N-demethyl-Ery (Fig. 3B). In the presence of 800 μM IS, intracellular N-demethyl-Ery was decreased by 36% (63.9 ± 4.1%), suggesting an inhibitory effect on Ery metabolism.

To further characterize the inhibitory effects of CMPF and IS on the uptake and metabolism of Ery, 2 μM Ery was incubated with rat hepatocytes in the presence of various concentrations of CMPF and IS. CMPF at concentrations of 25 μM (and higher) significantly reduced the intracellular accumulation of Ery (25.3 ± 1.8 versus 33.1 ± 0.8 pmol/million cells per 5 min; p < 0.05) (Fig. 4A) and at 50 μM and greater, decreased the intracellular N-demethyl-Ery (8.9 ± 0.6 versus 10.8 ± 0.5 pmol/million cells per 5 min; p < 0.05) (Fig. 4B). The inhibition was dose-dependent. The estimated IC₅₀ for CMPF on 2 μM Ery was 40.0 ± 1.2 μM. Ratios of intracellular N-demethyl-Ery to Ery were not significantly different from the control at CMPF concentrations of 200 μM and lower (Table 1), indicating that the reduced metabolite generation was due to limited uptake, not due to inhibited enzymatic metabolism. However, at the highest concentration of CMPF (400 μM), the ratio was significantly lower than that of control, suggesting the inhibited enzymatic metabolism was the primary effect, since the transporter-mediated uptake was already completely blocked at even lower concentrations of CMPF (Table 1).

In contrast, IS did not significantly affect the uptake of Ery (Fig. 5A), but it significantly reduced the intracellular levels of N-demethyl-Ery at higher concentrations (≥200 μM) (Fig. 5B). To further characterize the inhibitory effects of IS on the enzymatic metabolism of Ery.

---

**Fig. 4.** Dose-dependent inhibition of CMPF on Ery uptake by rat hepatocytes. The amount of intracellular Ery (A) and N-demethyl-Ery (B) in the presence of CMPF was expressed as the percentage of control (in the absence of CMPF). Each column and bar represents the mean ± S.E.M. (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Effects of Indoxyl Sulfate and CMPF on Microsomal Metabolism of Ery. To further examine whether CMPF and IS can directly inhibit the enzymatic metabolism of Ery, microsomal incubations of Ery (2 μM) in the presence of various concentrations of CMPF and IS were conducted. Both CMPF and IS could inhibit the metabolite formation of Ery at higher concentrations (≥200 μM for CMPF and ≥100 μM for IS) (Table 2). IS tended to have a stronger inhibitory effect on the enzymatic metabolism of Ery than of CMPF. At concentrations of 100 μM and greater (Table 2), IS significantly inhibited the metabolite formation by 31%.

Effects of Uremic Toxins on Ery Fluxes in MDRI-MDCK Cells. Ery transport in the B→A direction was larger than that in the A→B direction in MDRI-MDCK cells (B→A/A→B ratio = 64). The differential transport was significantly decreased in the presence of the P-gp inhibitor, GG918 (B→A/A→B ratio = 29). These results confirmed that Ery is a P-gp substrate. However, the uremic toxins, CMPF (500 μM and 1 mM), IS (1 mM), and HA (2 mM) had no significant effects on either the B→A or the A→B flux of Ery.

Discussion
In the present study, we investigated the effects of six uremic toxins, CMPF, indoxyl sulfate, hippuric acid, indole acetic acid, indoxyl-β-glucuronide, and guanidinouacetic acid, on the uptake of Ery using rat hepatocytes, and their effects on Ery metabolism using rat microsomes. Our results demonstrate that CMPF significantly inhibits the uptake of Ery by hepatocytes, mainly by inhibiting the liver uptake transporter Oatp, whereas at higher concentrations (≥200 μM), it appears to also inhibit the enzymatic metabolism of Ery. In contrast, indoxyl sulfate is more likely to inhibit the enzymatic metabolism of Ery and has no effect on hepatic uptake. In cellular bidirectional transport studies with Ery, we showed that neither CMPF nor indoxyl sulfate, the two uremic toxins affecting hepatocyte kinetics of Ery, could affect P-glycoprotein transport of Ery, a known P-gp substrate.

It has been previously reported that renal failure could alter hepatic clearance of drugs in many cases, although the underlying mechanisms remain unclear. Studies with the major metabolic enzyme system, P450, showed that specific isozymes were down-regulated in CRF rats such as CYP2C11, CYP3A1, and CYP3A2, but other isozymes such as CYP1A2 and CYP2D were unaffected (Leblond et al., 2000; Guevin et al., 2002). A detailed review of metabolic alterations in renal failure was recently published (Pichette and Leblond, 2003). Although the mechanisms responsible for the reduced metabolism are not known, studies suggest that uremic toxins may affect P450 promoters (Pichette and Leblond, 2003) and thereby cause down-regulation of certain P450 isoforms. Here, we show that uremic toxins can also directly affect P450 activity. Indoxyl sulfate and CMPF (at high concentrations) directly inhibit the N-demethylation of Ery mediated by CYP3A. This is consistent with previous findings of the effects of uremia on enzymatic metabolism (Yoshitani et al., 2002). For example, indoxyl sulfate was found to be able to inhibit losartan metabolism mediated by rat hepatic microsomes (Yoshitani et al., 2002). CMPF was shown to inhibit both phase I (O-demethylation) and phase II (glutathione conjugation and glucuronidation) pathways of drug metabolism in rabbit liver homogenates (Walters et al., 1995).

However, down-regulation or inhibition of the P450 system was not present or correlated with reduced hepatic clearance in many cases (Fillastre et al., 1980; Hori et al., 1985). We propose an alternative mechanism for the reduced hepatic clearance of drugs due to renal failure, that is, impaired hepatic uptake mediated by uptake transporters. With increasing awareness of the effects of hepatic transporters on drug disposition, our laboratory has investigated their importance in drug metabolism. Recent studies from our laboratory showed that decreased digoxin metabolism was found in the isolated perfused rat liver and rat hepatocytes during Oatp2 inhibition (Lau et al., 2004; Lam and Benet, 2004). The effect of uremic toxins on hepatic transporters had not previously been investigated, and although our studies were on rat hepatocytes, we believe that this work serves as a proof of concept example of the potential consequences of uremic toxins on hepatic drug disposition. In the present study, we showed that CMPF potently inhibited the uptake of Ery by rat hepatocytes and consequently reduced the metabolism of Ery. The effect of CMPF on Ery uptake appeared to be due to inhibition of Oatp2. Since transporters play an important role in the elimination of Ery, we expect that limited access of Ery to hepatocytes in the presence of CMPF would lead to less metabolism and less elimination into bile as well. We therefore suspect that inhibition of the hepatic uptake of Ery by circulating CMPF could at least in part account for the reduced hepatic clearance of Ery in ESRD patients. A recent study using the Ery breath test to measure metabolic activity in patients with renal failure found that the baseline metabolic activity was significantly lower than that of healthy volunteers (Dowling et al., 2003). We hypothesize that the reduced CO2 generation measured by the Ery breath test reflects decreased hepatic uptake of Ery.

The effects of renal failure on hepatic uptake of organic anions were documented in early studies (Yates et al., 1983; Bowmer and Yates, 1984). Studies showed that the hepatic uptake and initial biliary excretion of bromosulfophthalein were decreased in rats with glycerol-induced acute renal failure (Bowmer and Yates, 1984). A similar phenomenon was observed for another organic anion, indocyanine green (Yates et al., 1983). In addition, the kinetic changes of these organic anions were a consequence of renal failure, rather than a direct hepatotoxic effect of glycerol. Similar to erythromycin, the uptake of bromosulfophthalein and indocyanine green is mediated by the hepatic transporter Oatp (Jacquemin et al., 1994), and we believe that the reduced hepatic clearance of these organic anions is most likely the result of impaired uptake activity. Our results also may suggest a mechanism for the uremic effects on the hepatic uptake of thyroxin (Lim et al., 1993). CMPF and indoxyl sulfate, at concentrations normally present in uremic patients, were found to inhibit the uptake of thyroxin by rat hepatocytes (Lim et al., 1993). Oatps are the major transporters responsible for the uptake of thyroxin in liver (Fujiwara et al., 2001); therefore, the reduced hepatic uptake of thyroxin, bromosulfophthalein, and erythromycin is most likely due to inhibition of these uptake transporters by uremic toxins such as CMPF.

These findings may be helpful in understanding the reduced hepatic metabolism of Ery.

<table>
<thead>
<tr>
<th>Concentration (μM)</th>
<th>CMPFa</th>
<th>Indoxyl Sulfatea</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.33 ± 0.02</td>
<td>0.33 ± 0.01</td>
</tr>
<tr>
<td>10</td>
<td>0.33 ± 0.01</td>
<td>N.D.</td>
</tr>
<tr>
<td>25</td>
<td>0.39 ± 0.03</td>
<td>0.34 ± 0.02</td>
</tr>
<tr>
<td>50</td>
<td>0.38 ± 0.02</td>
<td>0.28 ± 0.01a</td>
</tr>
<tr>
<td>100</td>
<td>0.34 ± 0.03</td>
<td>0.27 ± 0.01b</td>
</tr>
<tr>
<td>200</td>
<td>0.32 ± 0.02</td>
<td>0.24 ± 0.01b</td>
</tr>
<tr>
<td>400</td>
<td>0.24 ± 0.01a</td>
<td>0.23 ± 0.01b</td>
</tr>
<tr>
<td>800</td>
<td>N.D.</td>
<td>0.22 ± 0.02b</td>
</tr>
</tbody>
</table>

N.D., not determined.
a Each value represents the mean ± S.E.M.
b p < 0.05, significantly different from controls.
clearance of other drugs in patients with renal failure. Studies with several statins all showed various degrees of reduced clearance in renal impairment [product information on Mevinacor (lovastatin), Cranoc (fluvastatin), and Zocor (simvastatin) and data in Querin et al. (1991)] that cannot be properly interpreted on the basis of decreased creatinine clearance alone. For instance, investigation of the pharmacokinetics of cerivastatin in renal impairment (Vormfelde et al., 1999) showed a significant increase of the unbound fraction ($f_u$) of the drug, but a doubling of its total area under the curve. The increased $f_u$ should lead to increased clearance of cerivastatin, but the opposite was found. The reduced clearance of cerivastatin was speculated to be due to impaired hepatic uptake since 70 to 80% of cerivastatin uptake was mediated by OATP in the liver (Shitara et al., 2003). The OATP-mediated uptake has also been demonstrated for other statins (Yamazaki et al., 1996; Hsiang et al., 1999), and animal experiments also showed that uptake into liver cells is the rate-limiting step in the hepatic clearance of pravastatin (Yamazaki et al., 1996). It was therefore proposed that progression of renal disease will reduce the expression and function of the uptake transporters in the liver and that this transporter has a low overall capacity. On the basis of the present study, we suggest that CMPF can significantly inhibit hepatic uptake transporters. Since CMPF has also been found to inhibit drug binding to albumin (Takamura et al., 1997), thereby increasing $f_u$, inhibition of

**TABLE 2**

<table>
<thead>
<tr>
<th>Concentrations ($\mu$M)</th>
<th>N-Demethyl-Ery*</th>
<th>Indoxyl Sulfate</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100.0 ± 2.4</td>
<td>100.0 ± 5.5</td>
</tr>
<tr>
<td>25</td>
<td>99.2 ± 1.0</td>
<td>99.7 ± 2.8</td>
</tr>
<tr>
<td>50</td>
<td>99.0 ± 1.2</td>
<td>91.8 ± 2.8</td>
</tr>
<tr>
<td>100</td>
<td>92.0 ± 3.1</td>
<td>79.3 ± 4.6*</td>
</tr>
<tr>
<td>200</td>
<td>85.1 ± 3.7*</td>
<td>81.2 ± 6.8*</td>
</tr>
<tr>
<td>400</td>
<td>80.5 ± 3.1*</td>
<td>76.3 ± 2.7*</td>
</tr>
<tr>
<td>800</td>
<td>72.6 ± 5.1*</td>
<td>69.1 ± 4.6*</td>
</tr>
</tbody>
</table>

* Each value represents mean ± S.E.M.

* $p < 0.05$, significantly different from control.
hepatic uptake by CMPF may be even greater than the observed reduction of fractional hepatic clearance of the statins. In chronic renal failure, circulating uremic toxins may occupy the liver uptake transporters and accumulate in the liver to a large extent, thereby suppressing the uptake transporters directly and indirectly (down-regulation). Further research is required to clarify the in vivo effects of these uremic toxins on hepatic drug metabolism and elimination.

In conclusion, our present studies show that CMPF can directly inhibit the Oatp-mediated uptake of erythromycin by rat hepatocytes, whereas indoxyl sulfate was more likely to inhibit the enzymatic metabolism of erythromycin. Therefore, both of these uremic toxins might be expected to contribute to the reduced hepatic clearance of erythromycin in patients with ESRD.

Acknowledgments. We thank Professor Masaki Otagiri and Professor Edward Lindup for the supplies of CMPF.

References

Address correspondence to: Dr. Leslie Z. Benet, Professor, Department of Biopharmaceutical Sciences, University of California San Francisco, 533 Parnassus, Room U-68, San Francisco, CA 94143-0446. E-mail: benet@itsa.ucsf.edu